798 related articles for article (PubMed ID: 33278462)
1. 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.
Forrestall KL; Burley DE; Cash MK; Pottie IR; Darvesh S
Chem Biol Interact; 2021 Feb; 335():109348. PubMed ID: 33278462
[TBL] [Abstract][Full Text] [Related]
2. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
Hajbabaie R; Harper MT; Rahman T
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
[TBL] [Abstract][Full Text] [Related]
3. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Amin SA; Banerjee S; Ghosh K; Gayen S; Jha T
Bioorg Med Chem; 2021 Jan; 29():115860. PubMed ID: 33191083
[TBL] [Abstract][Full Text] [Related]
4. In silico analysis of selected alkaloids against main protease (M
Garg S; Roy A
Chem Biol Interact; 2020 Dec; 332():109309. PubMed ID: 33181114
[TBL] [Abstract][Full Text] [Related]
5. Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode.
Lockbaum GJ; Henes M; Lee JM; Timm J; Nalivaika EA; Thompson PR; Kurt Yilmaz N; Schiffer CA
Biochemistry; 2021 Oct; 60(39):2925-2931. PubMed ID: 34506130
[TBL] [Abstract][Full Text] [Related]
6. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
Yang KS; Ma XR; Ma Y; Alugubelli YR; Scott DA; Vatansever EC; Drelich AK; Sankaran B; Geng ZZ; Blankenship LR; Ward HE; Sheng YJ; Hsu JC; Kratch KC; Zhao B; Hayatshahi HS; Liu J; Li P; Fierke CA; Tseng CK; Xu S; Liu WR
ChemMedChem; 2021 Mar; 16(6):942-948. PubMed ID: 33283984
[TBL] [Abstract][Full Text] [Related]
7. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
9. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
[TBL] [Abstract][Full Text] [Related]
10. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
11. Apigenin analogues as SARS-CoV-2 main protease inhibitors:
Farhat A; Ben Hlima H; Khemakhem B; Ben Halima Y; Michaud P; Abdelkafi S; Fendri I
Bioengineered; 2022 Feb; 13(2):3350-3361. PubMed ID: 35048792
[TBL] [Abstract][Full Text] [Related]
12. Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses.
Luttens A; Gullberg H; Abdurakhmanov E; Vo DD; Akaberi D; Talibov VO; Nekhotiaeva N; Vangeel L; De Jonghe S; Jochmans D; Krambrich J; Tas A; Lundgren B; Gravenfors Y; Craig AJ; Atilaw Y; Sandström A; Moodie LWK; Lundkvist Å; van Hemert MJ; Neyts J; Lennerstrand J; Kihlberg J; Sandberg K; Danielson UH; Carlsson J
J Am Chem Soc; 2022 Feb; 144(7):2905-2920. PubMed ID: 35142215
[TBL] [Abstract][Full Text] [Related]
13. In Silico Characterization of Masitinib Interaction with SARS-CoV-2 Main Protease.
Martínez-Ortega U; Figueroa-Figueroa DI; Hernández-Luis F; Aguayo-Ortiz R
ChemMedChem; 2021 Aug; 16(15):2339-2344. PubMed ID: 34142459
[TBL] [Abstract][Full Text] [Related]
14. Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin.
Kwofie SK; Broni E; Asiedu SO; Kwarko GB; Dankwa B; Enninful KS; Tiburu EK; Wilson MD
Molecules; 2021 Jan; 26(2):. PubMed ID: 33466743
[TBL] [Abstract][Full Text] [Related]
15. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.
Lockbaum GJ; Reyes AC; Lee JM; Tilvawala R; Nalivaika EA; Ali A; Kurt Yilmaz N; Thompson PR; Schiffer CA
Viruses; 2021 Jan; 13(2):. PubMed ID: 33503819
[TBL] [Abstract][Full Text] [Related]
16. First COVID-19 molecular docking with a chalcone-based compound: synthesis, single-crystal structure and Hirshfeld surface analysis study.
Alsafi MA; Hughes DL; Said MA
Acta Crystallogr C Struct Chem; 2020 Dec; 76(Pt 12):1043-1050. PubMed ID: 33273140
[TBL] [Abstract][Full Text] [Related]
17. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
18. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
[TBL] [Abstract][Full Text] [Related]
19. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
20. Macrolactin A as a Novel Inhibitory Agent for SARS-CoV-2 M
Bharadwaj KK; Sarkar T; Ghosh A; Baishya D; Rabha B; Panda MK; Nelson BR; John AB; Sheikh HI; Dash BP; Edinur HA; Pati S
Appl Biochem Biotechnol; 2021 Oct; 193(10):3371-3394. PubMed ID: 34212286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]